Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
28.92 USD | +0.35% | +2.63% | +0.45% |
10:04am | GSK sells remaining Haleon stake for GBP1.25 billion | AN |
08:13am | GSK raises $1.5 bln from sale of remaining Haleon stake | RE |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
- The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.
Strengths
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's high margin levels account for strong profits.
- This company will be of major interest to investors in search of a high dividend stock.
Weaknesses
- With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- The company's enterprise value to sales, at 3.67 times its current sales, is high.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+0.45% | 164B | C+ | ||
+32.36% | 694B | C+ | ||
+30.04% | 593B | B | ||
-1.60% | 371B | C+ | ||
+20.07% | 331B | B- | ||
+6.04% | 290B | C+ | ||
+14.45% | 239B | B+ | ||
+10.45% | 209B | B- | ||
-3.11% | 209B | A+ | ||
+9.27% | 169B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- PFE Stock
- Ratings Pfizer, Inc.